SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI.X is trending as the community anticipates potential listings on major exchanges like Upbit and Binance, with some speculating about an upcoming rate cut that may amplify gains. Traders are actively discussing price discrepancies across different platforms, as well as strategies for transferring and accumulating the token. Despite some concerns around exchange-related issues, there is a general sentiment of holding for long-term growth, with comparisons being drawn to Dogecoin's earlier success.

Aventus

Aventus ($AVT.X) is trending with community members highlighting its strong uptrend, potential breakout, and solid support levels, with many building their positions. The coin's strong volume and recent partnerships are also being discussed as potential catalysts. Bulls appear to be in control, eyeing new highs and anticipating a rally.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending as investors react to news of the company's substantial Ethereum holdings and speculate on upcoming catalysts like potential rate cuts and the overall direction of crypto markets. Community discussions revolve around the company's leadership, treasury strategy, and potential for significant growth as an Ethereum treasury. Some traders express bullish sentiment, while others remain cautious of volatility and potential dilution.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending due to a major AI partnership secured with China Merchants Group, leading to overnight gains and excitement around its AI capabilities and autonomous mobility potential. Community discussions highlight Baidu's strong performance compared to other Chinese tech companies and a general bullish sentiment towards undervalued Chinese equities, with some seeing it as a breakout opportunity with significant growth potential.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending with increased volume and a rising stock price, sparking community discussion about potential catalysts. Talking points include a Congress member's recent purchase, Goldman Sachs increasing its position, and speculation around upcoming government contracts related to AI and defense. Some investors are drawing comparisons to Palantir, while others point to a large short position as a potential squeeze opportunity.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is trending as traders discuss its potential, recent positive news, and relationship to Bitcoin's price movements.  Community members are watching for a breakout above key resistance levels, while others express frustration with the stock's price action despite positive developments.  Broader discussions include the impact of potential interest rate cuts and competition within the crypto exchange landscape.

RCI Hospitality Holdings, Inc. engages in the provision of live adult entertainment and dining experiences. It operates through the following segments: Nightclubs and Bombshells. The Nightclubs segment includes adult entertainment. The Bombshells segment involves the operation of restaurants and bars. The company was founded by Robert L. Watters in 1983 and is headquartered in Houston, TX.

RCI Hospitality Holdings Inc

RCI Hospitality ($RICK) is trending due to a bribery scandal involving executives and tax fraud allegations, leading to a stock tailspin despite some retail traders remaining optimistic about potential recovery. The community is actively discussing the indictments, potential management changes, and the long-term value of the company's real estate assets. Some investors express concerns about capital allocation and past management decisions.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending as investors discuss the implications of a recent FDA warning letter regarding marketing claims about compounded weight-loss drugs, with a strong debate on whether this is a buying opportunity or a sign of deeper issues. Community members are weighing the potential impact on the company's growth and brand, while also noting the high short interest and potential for a short squeeze. Some bulls are pointing to the company's expansion into men's health and home testing as reasons for optimism.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO.X is trending as the community discusses recent price movement and potential for gains, while also debating its long-term potential and the impact of a related token, XL1. Some traders are optimistic about an upcoming Layer 1 release and potential listings, while others express frustration with perceived pump-and-dump patterns and the lack of sustained growth.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as traders discuss its potential to catch up with other Chinese tech stocks like BABA and BIDU, fueled by strong call buying and breakout signals; community members are pointing to its attractive valuation. Optimism is building around potential catalysts, including a possible re-rating and expansion into new markets like Indonesia, though some express frustration over its historical underperformance relative to peers. Discussions also include the potential impact of the company's investments in AI and logistics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clinical stage biotech company Vaccinex’s ($VCNX) stock was up nearly 16% (1:54 pm ET) on Thursday afternoon after the company said it will provide an update on safety and efficacy data from its Alzheimer’s drug study, lifting retail sentiment.Rochester, N.Y.-based Vaccinex said it will present ‘promising’ new efficacy and safety data for a randomized, double-blind, phase 1b/2 SIGNAL-AD study for the treatment of Alzheimer’s disease. Its lead product candidate is related to studying pepinemab antibody, aimed at treating early stages of Alzheimer’s disease. The company’s last update on positive clinical findings from its SIGNAL-AD Phase 1b/2 trial were made in August.VCNX stock is up 19.53% this week.Retail sentiment on the stock turned ‘bullish’ (72/100) from ‘neutral’ (50/100) a week ago with message volumes climbing into the ‘high’ zone compared to ‘normal’ last week.<figure class="image"><img style="aspect-ratio:1308/370;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_24_at_10_54_58_PM_16e50ec661.png" alt="Screenshot 2024-10-24 at 10.54.58 PM.png" width="1308" height="370"><figcaption>VCNX sentiment meter as of 1:25 pm ET</figcaption></figure>Many Stocktwits users were optimistic about its prospects even though the company has faced headwinds this year due to a challenging macro environment for biotech companies.<stembedurl>https://stocktwits.com/Pbonk/message/590003737</stembedurl><stembedurl>https://stocktwits.com/Krystian_v/message/589974260</stembedurl>As on December 31, 2023, the company’s cash and cash equivalents and marketable securities stood at $1.5 million, down from $6.4 million as of Dec. 31, 2022. In Oct. 2023, the company raised $9.6 million from the sale of common stock and warrants.VCNX stock is down 71% year-to-date.For updates and corrections, email newsroom@stocktwits.com&nbsp;

Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens

The Rochester, N.Y.-based firm said it will present ‘promising’ new efficacy and safety data for the treatment of Alzheimer’s disease later this month.

Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens

Equity

What's Going On With Vaccinex Stock Wednesday?

Vaccinex shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warrants as well as the issuance of new warrants for common stock.
read more...

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Expect Topline Data for Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab for Alzheimer's Disease in Q3 2024 Company raised $17.9 million of new financing during Q4 2023 and Q1 2024 ROCHESTER...

Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Decrease in Short Interest

Vaccinex, Inc. (NASDAQ:VCNX - Get Free Report) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 8,800 shares, a decline of 40.5% from the...

Vaccinex to raise $1.5M through in a direct offering

Vaccinex to raise $1.5M through in a direct offering...

Vaccinex prices 193,000 shares at $7.77 in registered direct offering

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) ( Vaccinex or the Company ), a clinical-stage biotechnology company pioneering a differentiated approach to...

12 acciones de salud en movimiento durante la preapertura del 26/02/2024

Acciones al alza
ZyVersa Therapeutics (NASDAQ:ZVSA) avanzaron un 47,31% para establecerse en los 1,18 d lares durante la sesi n del pre-market del lunes.
Vaccinex (NASDAQ:VCNX) crecieron un 43,64...

Vaccinex Announces Multiple New Agreements for Access to ActivMAb  Antigen Virus Technology

Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb Drug Discovery Platform ActivMab platform enables the discovery and development of high value antibodies against...

Vaccinex trading halted, news pending

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.

Vaccinex Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

VCNX
Vaccinex Inc

Feed

News

Sentiment

Fundamentals

Info

Latest VCNX News

VCNX Vaccinex Inc